Making progress in treating multiple myeloma with total therapies: issue of complete remission and more
- 28 February 2008
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (8) , 1633-1636
- https://doi.org/10.1038/leu.2008.40
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapyLeukemia, 2008
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2British Journal of Haematology, 2008
- Suppression of abnormal karyotype predicts superior survival in multiple myelomaLeukemia, 2008
- Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression ProfilingClinical Cancer Research, 2007
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisBlood, 2007
- Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseBritish Journal of Haematology, 2006
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosisBlood, 2006
- Complete response in myeloma: a Trojan horse?Blood, 2006
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984